Jupiter Neurosciences Faces Delisting Concerns
Ticker: JUNS · Form: 8-K · Filed: Mar 25, 2025 · CIK: 1679628
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Jupiter Neurosciences might get delisted, big trouble for the stock.
AI Summary
Jupiter Neurosciences, Inc. filed an 8-K on March 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerly known as Jupiter Orphan Therapeutics, Inc., is incorporated in Delaware and has its principal executive offices in Jupiter, Florida.
Why It Matters
This filing indicates potential issues with Jupiter Neurosciences' continued listing on an exchange, which could significantly impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ability to remain publicly traded.
Key Numbers
- 001-41265 — SEC File Number (Identifier for the company's filings)
- 47-4828381 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- JUPITER NEUROSCIENCES, INC. (company) — Registrant
- Jupiter Orphan Therapeutics, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- 1001 North US HWY 1 , Suite 504 , Jupiter , FL 33477 (address) — Principal executive offices
- March 21, 2025 (date) — Date of earliest event reported
- March 25, 2025 (date) — Date of report
FAQ
What specific listing rule or standard has Jupiter Neurosciences failed to satisfy?
The filing does not specify the exact rule or standard that Jupiter Neurosciences has failed to satisfy, only that a notice has been issued.
What is the expected timeline for addressing the delisting concerns?
The filing does not provide a specific timeline for addressing the delisting concerns.
Has Jupiter Neurosciences taken any steps to rectify the situation leading to the notice?
The filing does not detail any specific actions taken by Jupiter Neurosciences to rectify the situation.
What are the potential consequences if the company cannot satisfy the listing requirements?
The primary consequence would be the delisting of the company's securities from the exchange where they are currently listed.
When was the company formerly known as Jupiter Orphan Therapeutics, Inc.?
The company's name changed from Jupiter Orphan Therapeutics, Inc. on July 13, 2016.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 25, 2025 regarding JUPITER NEUROSCIENCES, INC. (JUNS).